Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03203837 · ClinicalTrials.gov registry record
Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere®
A clinical trial, sponsored by Northwestern University.
- Terminated
- Registry status
- 4
- Enrollment target
NCT03203837: Clinical Trial study, sponsored by Northwestern University.
NCT03203837 is a clinical trial that was terminated before completion, run by Northwestern University. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03203837 was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- 4 participants
- Enrollment target
Study Summary
To analyze specific angiogenic, inflammatory and immune profiles in hepatocellular carcinoma patients who undergo radioembolization.
Primary Outcome
The percent of change at 7 different timepoints for the following biomarkers will be calculated: Ang-2, FGFb, HB-EGF, HGF, PDGF-BB, PIGF, SDF-1, VEGF, VEGFC, IFNg, IL-1a, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, TNFa trimer, CRP, TGFb1, EGFR, PD-1, PD-L1, CD45RA, CD127, HLA-DR, CD62L, CD3, CD8, CD197, CCR7, CD45RO, PD-L2, FOXP3, Perforin, Granzyme, TIA-1, CD14, CD107a, CD25, CD45, CD4, CD20 and CD56+16.
Interventions
- OTHER Plasma collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2017-07-05 |
| Est. Completion | 2020-01-06 |
Why NCT03203837 stopped before completion
NCT03203837 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 4 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Plasma collection is the first listed.
NCT03203837 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03203837 about?
NCT03203837 is a clinical study titled "Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere®". To analyze specific angiogenic, inflammatory and immune profiles in hepatocellular carcinoma patients who undergo radioembolization.
What is the current status of trial NCT03203837?
This trial is currently terminated. The enrollment target is 4 participants. The study started on 2017-07-05. Estimated completion is 2020-01-06.
What interventions are being tested in trial NCT03203837?
The interventions under investigation include: Plasma collection (OTHER).
Who is sponsoring clinical trial NCT03203837?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI